Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 11.37
(-0.26%)
CNY 11.37
(-0.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -170.79 Million CNY | -249.98% |
| 2022 | 113.87 Million CNY | -76.19% |
| 2021 | 478.28 Million CNY | -32.56% |
| 2020 | 709.18 Million CNY | -33.18% |
| 2019 | 1.06 Billion CNY | 41.12% |
| 2018 | 752.1 Million CNY | 131.34% |
| 2017 | 325.1 Million CNY | 624.27% |
| 2016 | 44.88 Million CNY | 1885.21% |
| 2015 | -2.51 Million CNY | -102.22% |
| 2014 | 113.13 Million CNY | 356.37% |
| 2013 | 24.79 Million CNY | 317.48% |
| 2012 | -11.39 Million CNY | -538.15% |
| 2011 | 2.6 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -85.12 Million CNY | 50.16% |
| 2024 Q3 | -346.57 Million CNY | -234.21% |
| 2024 Q2 | -101.2 Million CNY | -18.89% |
| 2023 Q4 | -170.79 Million CNY | -522.5% |
| 2023 Q3 | 40.42 Million CNY | -52.1% |
| 2023 Q1 | -70.1 Million CNY | -161.57% |
| 2023 FY | -170.79 Million CNY | -249.98% |
| 2023 Q2 | 84.38 Million CNY | 220.36% |
| 2022 Q4 | 113.87 Million CNY | 146.74% |
| 2022 Q3 | 46.15 Million CNY | 113.37% |
| 2022 Q2 | -345.06 Million CNY | -115.46% |
| 2022 FY | 113.87 Million CNY | -76.19% |
| 2022 Q1 | -160.15 Million CNY | -133.48% |
| 2021 FY | 478.28 Million CNY | -32.56% |
| 2021 Q4 | 478.28 Million CNY | -38.28% |
| 2021 Q1 | 877.93 Million CNY | 23.8% |
| 2021 Q2 | 1.03 Billion CNY | 18.06% |
| 2021 Q3 | 774.92 Million CNY | -25.24% |
| 2020 Q4 | 709.18 Million CNY | -33.83% |
| 2020 FY | 709.18 Million CNY | -33.18% |
| 2020 Q2 | 1.13 Billion CNY | 8.12% |
| 2020 Q1 | 1.05 Billion CNY | -0.84% |
| 2020 Q3 | 1.07 Billion CNY | -5.81% |
| 2019 Q4 | 1.06 Billion CNY | -14.96% |
| 2019 Q3 | 1.24 Billion CNY | 16.91% |
| 2019 Q2 | 1.06 Billion CNY | 15.57% |
| 2019 Q1 | 923.69 Million CNY | 22.82% |
| 2019 FY | 1.06 Billion CNY | 41.12% |
| 2018 FY | 752.1 Million CNY | 131.34% |
| 2018 Q2 | 677.91 Million CNY | 14.52% |
| 2018 Q1 | 591.94 Million CNY | 82.08% |
| 2018 Q4 | 752.1 Million CNY | -5.89% |
| 2018 Q3 | 799.16 Million CNY | 17.89% |
| 2017 Q1 | 75.39 Million CNY | 67.98% |
| 2017 FY | 325.1 Million CNY | 624.27% |
| 2017 Q4 | 325.1 Million CNY | 13.96% |
| 2017 Q3 | 285.27 Million CNY | 76.33% |
| 2017 Q2 | 161.78 Million CNY | 114.56% |
| 2016 FY | 44.88 Million CNY | 1885.21% |
| 2016 Q4 | 44.88 Million CNY | -77.09% |
| 2016 Q3 | 195.94 Million CNY | 12.05% |
| 2016 Q2 | 174.87 Million CNY | 67.54% |
| 2016 Q1 | 104.37 Million CNY | 4251.26% |
| 2015 Q1 | 245.75 Million CNY | 117.22% |
| 2015 FY | -2.51 Million CNY | -102.22% |
| 2015 Q4 | -2.51 Million CNY | 86.81% |
| 2015 Q3 | -19.06 Million CNY | 97.52% |
| 2015 Q2 | -768.04 Million CNY | -412.52% |
| 2014 FY | 113.13 Million CNY | 356.37% |
| 2014 Q4 | 113.13 Million CNY | 0.0% |
| 2014 Q1 | 105.91 Million CNY | 0.0% |
| 2013 FY | 24.79 Million CNY | 317.48% |
| 2012 FY | -11.39 Million CNY | -538.15% |
| 2011 FY | 2.6 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 112.955% |
| Hangzhou Tigermed Consulting Co., Ltd. | -4.06 Billion CNY | 95.796% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | -29.76% |
| Beijing Strong Biotechnologies, Inc. | 411.59 Million CNY | 141.496% |
| Medicalsystem Biotechnology Co., Ltd. | -850.71 Million CNY | 79.924% |
| Guangzhou Wondfo Biotech Co.,Ltd | -240.75 Million CNY | 29.06% |
| Guangdong Hybribio Biotech Co.,Ltd. | -708.27 Million CNY | 75.886% |
| BGI Genomics Co., Ltd. | -3.63 Billion CNY | 95.303% |
| Amoy Diagnostics Co., Ltd. | -92.73 Million CNY | -84.179% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -486.57 Million CNY | 64.899% |